626P Roginolisib (IOA-244), a first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) in patients with metastatic uveal melanoma.
Saved in:
| Title: | 626P Roginolisib (IOA-244), a first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) in patients with metastatic uveal melanoma. |
|---|---|
| Authors: | Di Giacomo, A.M.1 (AUTHOR), Simonelli, M.2 (AUTHOR), Santangelo, F.3 (AUTHOR), Amato, G.1 (AUTHOR), Simonetti, E.4 (AUTHOR), Graham, J.5 (AUTHOR), Lahn, M.6 (AUTHOR), Di Conza, G.7 (AUTHOR), Hammett, T.8 (AUTHOR), Zorrilla, R.8 (AUTHOR), Kaur, P.9 (AUTHOR), Ziyang, T.10 (AUTHOR), Lakshmikanth, T.10 (AUTHOR), Brodin, P.10 (AUTHOR), Occhipinti, M.11 (AUTHOR), Carlo-Stella, C.12 (AUTHOR), Santoro, A.13 (AUTHOR), Spiliopoulou, P.14 (AUTHOR), Evans, T.R.J.15 (AUTHOR), Maio, M.16 (AUTHOR) |
| Source: | Annals of Oncology. 2024 Supplement 2, Vol. 35, pS500-S500. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2024.08.693 |
